

1 **Field-deployable molecular diagnostic platform for arbovirus and *Wolbachia* detection in**

2 *Aedes aegypti*

3

4 Natalie N. Rutkowski, Yuemei Dong, and George Dimopoulos*

5

6 W. Harry Feinstone Department of Molecular Microbiology and Immunology, Bloomberg

7 School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of

8 America

9

10 *Correspondence should be addressed to GD

11 E-mail: gdimopo1@jhu.edu

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26 **Abstract**

27 **Background:** Surveillance of mosquito infection status is critical for planning and deployment
28 of proper mosquito control initiatives. Concurrently, *Wolbachia* is being widely used as a control
29 method for arboviral transmission. Point-of-care (POC) detection assays are necessary for
30 monitoring the infection prevalence and geographic range of viruses as well as *Wolbachia* in
31 mosquito vector populations. We therefore assessed the novel qPCR bCUBE molecular
32 diagnostic system as a tool for virus and *Wolbachia* detection.

33 **Results:** We developed a reliable, specific, and sensitive diagnostic assay for detecting Zika
34 virus and dengue virus serotype 2 using the real-time qPCR platform bCUBE. With bCUBE-
35 based qRT-PCR, both *Wolbachia* bacterium and virus RNA could be reliably detected in
36 individually infected *Ae. aegypti* mosquitoes and in pools of 5, 10, or 15 mosquitoes.

37 **Conclusions:** The portable qPCR bCUBE diagnostic platform is capable of detecting Zika and
38 dengue virus as well as *Wolbachia* in mosquitoes and therefore has potential as a practical field-
39 deployable diagnostic test for vector-borne disease surveillance programs.

40

41

42

43

44

45

46

47

48 **Keywords:** *Aedes aegypti*, Zika, dengue, diagnostics, qPCR

49 **Introduction**

50 Arthropod-borne diseases threaten over two-thirds of the global population and are exhibiting an
51 ongoing expansion of their geographic range and prevalence as a result of climate change,
52 urbanization, and globalization (1-4). According to the World Health Organization, dengue virus
53 infection has increased 30-fold over the past 50 years and now affects nearly 100 million people,
54 primarily in the Americas and Asia (5, 6). Recent outbreaks of Zika virus have also led to
55 widespread concern because of the virus's ability to cause newborn malformations (7, 8).

56

57 Dengue and Zika viruses are members of the genus *Flavivirus* that are primarily transmitted by
58 the *Aedes* mosquito (7, 9, 10). Other members of the *Flavivirus* genus are also recognized as
59 vector-borne pathogens of public health significance, including West Nile virus (WNV), yellow
60 fever virus (YFV), Japanese encephalitis virus (JEV), and Chikungunya virus (CHIKV). These
61 viruses result in similar flu-like symptoms with the potential to progress to neuroinvasive
62 outcomes. *Aedes* mosquitoes, with their aggressive blood-feeding behavior, have allowed for
63 efficient human-mosquito transmission of these arboviruses (3, 11). The geographical presence
64 of this mosquito vector has dramatically increased in the last few decades, leading to an
65 expanded transmission of these arboviruses (12-14). The lack of vaccines and treatment against
66 these arboviruses highlights the importance of mosquito control and surveillance strategies (15).
67 Current and future mosquito-targeted control strategies are, and will be, having a significant
68 epidemiological impact but also require mosquito and pathogen surveillance (15). Surveillance
69 of geographical distribution of the vector mosquitoes and the pathogens they carry is an essential
70 component of disease prevention and control.

71

72 *Wolbachia pipientis* is increasingly being used as a method for limiting arboviral transmission in
73 dengue and Zika virus-endemic countries. This endosymbiotic bacterium is passed from mother
74 to offspring and has been shown to suppress dengue and Zika virus transmission in *Aedes*
75 mosquitoes (16, 17). Field-release trials require continual monitoring of *Wolbachia*-infected *Ae.*
76 *aegypti* in mosquito populations (18-20). Real-time qPCR has been used as the primary method
77 for detecting *Wolbachia* genetic material in mosquitoes (21).

78

79 Accurate, rapid, and cost-effective mosquito and pathogen surveillance is critical for monitoring
80 infection prevalence and thereby mitigating transmission risk. Methods currently used for
81 arboviral detection include viral culture, antibody detection, antigen detection, and RNA
82 detection using quantitative real-time RT-PCR (qPCR). Currently, the qPCR method is the gold
83 standard because of its use of specific molecular markers (22, 23). Many of these assays are
84 laborious and laboratory-based and require expensive and bulky instruments, making them
85 incompatible with low-resource regions (24). Recently, several novel, advanced point-of-care
86 (POC) diagnostic measures have been developed for detecting mosquito-borne viruses in the
87 field, including honey-baited nucleic acid preservation cards (25, 26), loop-mediated isothermal
88 amplification (LAMP) (27), biosensors (28), and adaptations of near-infrared spectrometry
89 techniques (29). However, these techniques have documented limitations, including cross-
90 reactivity with other flaviviruses or requirements for training on specialized equipment, making
91 the adoption of these new diagnostic tools difficult (30, 31). Although the global burden of
92 emerging outbreaks of Zika and dengue is clearly recognized, there is a gap in resources for
93 endemic countries and regions, which are consistently plagued by a lack of equipment and

94 adequate resources to consistently monitor the prevalence and range of infected mosquitoes (5,
95 32, 33).

96

97 Disease surveillance and integrated vector control are essential for curbing disease transmission.

98 Nucleic acid-based testing to detect viral RNA allows for specific and sensitive virus monitoring

99 in mosquito surveillance programs (24). Several conventional and more recent real-time PCR-

100 based assays have been established for mosquitoes and their vectored pathogens, and the ready

101 availability of genome sequences for both vectors and pathogens can support the identification of

102 additional PCR-compatible molecular markers (34-36).

103

104 In the present study, we evaluated a novel and portable real-time PCR platform, bCUBE (Hyris,

105 Ltd), as a PCR-based arboviral detection method with potential for field-deployability. bCUBE

106 makes possible the genetic testing of biological samples in any setting, at any time, with real-

107 time access to results on its dedicated cloud-based software platform. This technology is a

108 portable device, similar in size to a Bluetooth speaker, which is used for biological analysis in

109 several fields, including agricultural pest control. The device can be operated from a laptop,

110 tablet, or cellular device through an easy-to-use gateway and generates centralized data analysis

111 immediately after a reaction. The device is capable of performing thermocycling reactions such

112 as real-time PCR, as well as loop-mediated isothermal amplification (LAMP). The system can be

113 calibrated to distinguish between positive and negative samples in a single reaction with

114 predetermined conditions that have been established ahead of time in the laboratory. This

115 feature allows the bCUBE to be operated by individuals lacking in depth training in qPCR assays

116 and data analysis skills. We have now explored the use of bCUBE technology for detection of

117 both dengue and Zika virus in *Aedes aegypti*, optimizing and standardizing the sample
118 preparation method to be used with a commercially available one-step qRT-PCR assay kit.
119 Finally, we have developed a bCUBE-compatible qPCR diagnostic assay for the surveillance of
120 arboviral pathogens and *Wolbachia* in *Aedes* mosquitoes.

121

122 **Methods**

123 **Ethical Statement.** This study was carried out in strict accordance with the recommendations in
124 the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH).
125 Mice were used according to an animal protocol (permit # MO15H144) approved by the Animal
126 Care and Use Committee of the Johns Hopkins University and were used as the blood source for
127 the maintenance of the mosquito colonies. Commercial anonymous human blood (InterState
128 Blood Bank) was used for Zika and dengue virus infection assays in mosquitoes, and informed
129 consent was therefore not applicable.

130

131 **Mosquito rearing and mosquito infections.** *Ae. aegypti* Liverpool strain LVPB12 mosquitoes
132 were maintained on 10% sucrose solution under standard insectary conditions at $27\pm 0.5^{\circ}\text{C}$ and
133 75-80% humidity with a 12-h light/dark cycle. Mosquitoes were reared using a standard rearing
134 protocol, and colonies were maintained on Swiss Webster mice (Charles River Laboratories).
135 DENV2 and ZIKV infection of mosquitoes was carried out as previously described (37). Virus
136 supplemented blood was fed to mosquitoes using an artificial membrane glass feeder, and
137 infected mosquitoes were double-caged and incubated in a reach-in incubator under conditions
138 similar to those in the standard insectary chamber described above. *Wolbachia* wAlbB-infected

139 *Ae. aegypti* (WB1) mosquitoes were reared and maintained under the standard insectary
140 conditions described above and in (38).

141
142 **Cell culture and virus propagation.** *Aedes albopictus* C6/36 cells (ATCC CRL-1660) were
143 cultured, and viral stocks were prepared as previously described in (39). In brief, C6/36 cells
144 were cultured in MEM medium (Gibco) supplemented with 10% heat-inactivated fetal bovine
145 serum (FBS), 1% penicillin-streptomycin, and 1% non-essential amino acids and maintained in a
146 tissue culture incubator at 32°C and 5% CO₂. Baby hamster kidney strain 21 (BHK-21, ATCC
147 CCL-10) cells were maintained at 37°C and 5% CO₂ in the DMEM medium (Gibco)
148 supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 5µg/ml
149 PlasmocinTM. DENV serotype 2 New Guinea C strain (DENV2) and ZIKV strain FSS 13025
150 (ZIKV) were used in the indicated experiments. For viral stock preparation, C6/36 cells grown to
151 80% confluence were infected with ZIKV and DENV2 at a multiplicity of infection (MOI) of 10
152 and incubated at 32°C and 5% CO₂ for 5 days (DENV2) and 6 days (ZIKV). Virus was
153 harvested by three freeze-thaw cycles using dry ice and a water bath (37°C), then centrifuged at
154 2,000 rpm for 10 min at 4°C. The supernatant from this cell lysis was mixed with the original
155 cell culture supernatant to yield the final viral stock. Viral stocks were aliquotted and stored at -
156 80°C for long-term storage. Viral stock titration was done by plaque assay as described below.
157

158 **Primer design for real-time quantitative RT-PCR (qPCR).** The ZIKV envelope (E) protein
159 was chosen as the target for ZIKV detection, and primers were developed based on previously
160 established sequences (40). Dengue virus serotype 2 (DENV2) qPCR was performed using
161 previously developed protocols that employ primers detecting serotype 2 in the 3'UTR region

162 (41) (Table 1). The primers were modified and optimized for bCUBE qPCR (Table 1). Primer
 163 sequences were assessed with NCBI Blast to search for potential cross-reactivity against other
 164 viruses, bacteria, and vectors. Previously established primers for *wAlbB* detection were used for
 165 *Wolbachia*-infected *Ae. aegypti* (42). The sequences of the primers are summarized in Table 1.

Primer	Sequence 5'-3'	Nucleotide position	Amplicon size (bp)	Accession Number	Reference
ZIKV-forward	AGCAACATGGCGGAGGTAAG	1,128-1,147	145	FSS13025	(34)*
ZIKV-reverse	CTGTCCACTAACGTTCTTTTGCAGA	1,249-1,273			
DENV-2-forward	TCCCTTCCAAATCGCAGCAACAATG	10,517-10,541	168	NC_001474.2	(35)*
DENV-2-reverse	CGTTCTGTGCCTGGAATGATG	10,665-10,685			
wAlbB-forward	CCTTACCTCCTGCACAACAA	213,522-213,541	110	CP031221.1	(36)
wAlbB-reverse	GGATTGTCCAGTGGCCTTA	213,394-213,412			
WNV-forward	TTGTGTTGGCTCTCTTGGCGTTCTT	233-257	408	AF196835	(38)
WNV-reverse	CAGCCGACAGCACTGGACATTCATA	640-616			
JEV-forward	GGCAGAAAGCAAAACAAAAGA	390-410	367	AF080251	(39)
JEV-reverse	CGGATCTCCTGCTTCGCTTGG	736-756			
YFV-forward	CACGGCATGGTTCCCTTCCA	5,656-5,674	71	MN708497	(37)
YFV-reverse	ACTCTTTCCAGCCTTACGCAAA	5,707-5,728			
CHIKV-forward	TACAGGGCTCATACCGCATC	10,357-10,376	154	NC_004162	(40)
CHIKV-reverse	AAAGGTGTCCAGGCTGAAGA	10,492-10,511			

166

167 **Table 1. Primer pairs for viral detection and cross-reactivity panel for real-time qPCR**
 168 **using the bCUBE.**

169 *ZIKV and DENV-2 primers were modified and optimized for qRT-PCR. The cross-reactivity
 170 panel primer sequences were included to confirm viral RNA obtained from BEI Resources. Four
 171 viruses were included in this study: West Nile virus (WNV), Japanese encephalitis virus (JEV),
 172 yellow fever virus (YFV), and Chikungunya virus (CHIKV). Primer sequence, nucleotide
 173 position, and amplicon size are listed.

174

175 **Cross-reactivity panel of mosquito-borne viruses.** Viral nucleic acid sequences included in the
 176 cross-reactivity panel were CHIKV (H20235 ST MARTIN 2013), JEV (India R53567), WNV
 177 (CO 1862), and YFV (17D), obtained from BEI Resources. A NanoDrop Spectrophotometer
 178 (ThermoFisher Scientific) was used to measure the RNA concentration of these viral samples.

179 Previously established primers were used, as listed in Table 1, for qPCR to confirm the presence
180 of corresponding viral RNA in the samples (43-46).

181

182 **Total RNA preparation for DENV2- and ZIKV-infected whole mosquitoes or tissues.** Total

183 RNA extraction was performed using a squash buffer (10 mM Tris base, 1 mM EDTA, 50 mM

184 NaCl) supplemented with 1:8 part Proteinase K (Qiagen, 15mg/ml). Mosquito abdomens with

185 the midguts and heads with thoraces were individually collected in 50 µl of squash buffer at 7

186 and 14 days, respectively, after an infectious blood meal and stored at -80°C until extracted.

187 Proteinase K was added at 1/8 volume to each sample to give a final concentration of 15 mg/ml

188 and homogenized with a cordless Pellet Pestle Motor (Kontes) for 40-60 s. Samples were

189 incubated at 57°C for 5 min, followed by 95°C for 5 min for enzyme deactivation. The

190 supernatant from this crude RNA extraction was used immediately for qPCR or stored at -80°C

191 until use.

192

193 **gDNA preparation of *Wolbachia*-infected mosquitoes.** Total gDNA from *Wolbachia*-infected

194 total mosquitoes or tissues was prepared as described above (47). These crude gDNA extractions

195 were immediately used for qPCR or stored at -80°C until use.

196

197 **Laboratory standard real-time PCR with Applied Biosystems equipment.** A StepOnePlus

198 Real-Time PCR system (Applied Biosystems) was used for comparative analysis. The mosquito

199 housekeeping gene ribosomal protein S17 (*rps17*) was amplified in *Aedes aegypti* using the two

200 different PCR machines (Applied Biosystems and bCUBE) with the same real-time PCR

201 settings. SYBR Green PCR Master Mix (Applied Biosystems) was used according to

202 manufacturer's instructions. Mosquitoes were collected individually in 50 µl of squash buffer,
203 and crude gDNA was extracted. Identical samples were applied to both the bCUBE- and
204 StepOnePlus-based qPCR systems for comparative evaluation.

205

206 **Hyris bCUBE real-time RT-PCR.** The portable qPCR machine Hyris bCUBE 2.0 thermocycler
207 (Hyris, London, UK) and the 16-well cartridges were kindly provided by Hyris Inc. The Hyris
208 data analysis platform was used for this study. GoTaq 1-Step RT-qPCR kit (Promega) was used
209 at a final volume of 20 µl with: 0.4 µl of kit reverse transcriptase enzyme, 10 µl of RT-PCR
210 buffer, 0.3 µl of 10 µM of forward and reverse primer, 9 µl of DNA/RNA free water, and 1 µl of
211 crude RNA or gDNA sample. Each sample was performed in technical duplicate. Each cartridge
212 run included one negative and one positive control. The following thermocycling settings were
213 used: reverse transcription for 15 min at 37°C, heat-inactivation of reverse transcriptase at 95°C
214 for 10 min, followed by 30 PCR cycles at 95°C for 10 s, 60°C for 30 s, and 72°C for 30 s.
215 Melting curve analysis was performed at the end by cooling to 60°C, followed by heating to
216 95°C at 0.05°C/s. Automatic data analysis was generated with the Hyris data analysis platform.
217 Two technical replicates were performed on the platform for each biological replicate. Three
218 biological replicates were included for each assay.

219

220 **Absolute quantification of viral copy numbers through qRT-PCR.** *In vitro*-transcribed RNA
221 of the E gene of ZIKV and the 3'-UTR region of DENV2 were used for absolute quantification
222 and cloned into a TOPO-TA vector. Total RNA was extracted using TRIzol reagent
223 (ThermoFisher Scientific). RNA (2 µg) was used for cDNA synthesis with M-MLV Reverse
224 Transcriptase (Promega). Conventional PCR was used with the primer (Table 1) to amplify a

225 DNA fragment of 168-bp for DENV2 and 145-bp for ZIKV. PCR was followed by PCR
226 purification using a QIAquick PCR Purification kit and protocol (Qiagen). About 50 ng of
227 cleaned PCR product of either DENV2 or ZIKV was separately cloned into a TOPO-TA PCR
228 cloning vector (ThermoFisher Scientific) according to the manufacturer's instructions. The
229 ligation product was transformed with TOP10-competent cells (ThermoFisher Scientific), and
230 positive clones grown on LB selection agar plates were screened through colony-PCR, followed
231 by plasmid mini-prep (Qiagen) and sequencing confirmation. The plasmids of the final
232 confirmed-positive clones were purified using the Maxiprep kit (Qiagen) according to the
233 manufacturer's instructions. Plasmid DNA was used to prepare absolute standards. A HiScribe
234 T7 High Yield RNA Synthesis Kit (NEB) was used for RNA synthesis, and the concentration of
235 the RNA was checked with a NanoDrop Spectrophotometer (ThermoFisher Scientific).
236 Molecular weights were converted to copy numbers using the New England BioLabs Calculator
237 (<https://nebiocalculator.neb.com/#!/ssrnaamt>). The concentration of RNA was adjusted to 10^{10}
238 copies/ μ l and serially diluted 10 times for the standard curve on the bCUBE. The standard curve
239 was generated using GoTaq 1-Step RT-qPCR (Promega).

240

241 **Viral titration by plaque assay.** The titers of ZIKV and DENV2 in the original viral stocks and
242 in the infected mosquitoes were determined by plaque assays in BHK-21 cells. Each experiment
243 was performed with at least three biological replicates. Whole mosquito or mosquito tissue
244 samples were collected at 7 and 14 days post-infectious blood meal in 150 μ l of complete
245 DMEM medium with glass beads. Tissue samples were homogenized with a Bullet Blender
246 (Next Advance) and serially diluted with DMEM complete medium. One or two days before
247 plaque assay, the BHK-21 cells were split at a 1:10 dilution and grown on 24-well plates to 80%

248 confluency. Serially diluted mosquito or viral samples (100 μ l each) were added to the BHK-21
249 cells, followed by incubation at room temperature for 15 min on a rocking shaker (VWR) and
250 subsequent incubation at 37°C with 5% CO₂ in a cell incubator (ThermoScientific) for another
251 45 min. The 24-well plates with infected BHK-21 cells were overlaid with 1 ml of 0.8%
252 methylcellulose in complete DMEM medium with 2% FBS and incubated for 5 to 6 days in the
253 cell culture incubator (37°C and 5% CO₂). Plaques were fixed and developed with staining
254 reagent (1% crystal violet in 1:1 methanol/acetone solution) at room temperature for
255 approximately 30 min. Plates were rinsed with DI water and air-dried, and plaques were counted
256 and multiplied by the dilution factor to calculate the plaque forming units (PFUs) per sample.
257

258 **DENV2 and ZIKV mosquito pools.** Preliminary pooled sample experiments involved a total of
259 300 *Aedes aegypti*: 276 uninfected, 12 infected with DENV2 and 12 infected with ZIKV. First,
260 12 mosquitoes were infected with ZIKV and 12 with DENV2. Following confirmation of
261 infection by RT-qPCR of individual infected mosquitoes, each was placed into a pool of
262 uninfected mosquitoes. Four different pools were used to measure the sensitivity of the infection
263 detection for pools of 5, 10, 15, and 20. The squash buffer volumes used were 250, 450, 700, and
264 950 μ l, respectively, followed by the addition of 1:8 part Proteinase K.


265
266 **Statistical Analysis.** Graphs were generated using GraphPad Prism Software version 8. The
267 estimation of several diagnostic parameters for leg samples, including sensitivity, specificity,
268 accuracy, and positive and negative predictive values was calculated using the web-based
269 software MedCalc Diagnostic Test Evaluation Calculator.

270

271 **Results**

272 **The reliability of the portable bCUBE qPCR machine is equal to that of a laboratory-**
273 **standard qPCR system**

274 The reliability of the novel bCUBE real-time PCR system was validated by comparing the
275 system to a standard qPCR instrument (Applied Biosystems StepOnePlus, ABI). Our proof-of-
276 principle studies used mosquito tissue homogenates (abdomen with the midgut, and head with
277 the thorax) in squash buffer that were tested with the mosquito housekeeping gene (ribosomal
278 protein S17, *rps17*). *Aedes aegypti* were dissected into crude compartments, including the
279 abdomen and head plus thorax. Identical samples were processed using both qPCR machines,
280 identical settings, and identical SYBR Green Master Mix and instructions (Applied Biosystems).
281 As shown in Fig. 1, the housekeeping *Rps17* gene was detected in all 24 samples by both
282 machines. The cycle threshold (Ct) values for the *Rps17* gene in *Ae. aegypti* were detected
283 significantly earlier in the bCUBE system than in the laboratory standard procedure, with a mean
284 difference of 2.40 Ct value (paired t-test, p -value < 0.0001). This result suggests that the bCUBE
285 qPCR is reliable in detecting a mosquito gene from a single mosquito tissue using a crude
286 sample-preparation method.



287

288 **Fig. 1. Comparison of *Ae. aegypti* *Rps17* gene detection in abdomen (ABD) and head plus**
289 **thorax (HT) samples using bCUBE and Applied Biosystems real-time PCR.** *Ae. aegypti*
290 abdomens and head plus thoraces were collected, and gDNA was extracted using the squash
291 buffer method. The housekeeping gene *Rps17* was amplified using the bCUBE and Applied
292 Biosystems real-time PCR systems. Cycle threshold (Ct) values are plotted. Statistical
293 significance was determined by Mann-Whitney test (****, $p < 0.0001$; Mann-Whitney).
294

295 **bCUBE-based one-step qRT-PCR is sufficiently sensitive for DENV2 and ZIKV detection**

296 We performed sensitivity studies on the bCUBE-based qPCR system based on absolute
297 quantification standard curve analysis. Cloned fragments of DENV2 and ZIKV were quantitated
298 for RNA copy number and serially diluted to establish a qPCR standard curve. End-point
299 limitations were set to < 30 for Zika virus, whereas dengue end-point limitations were set to < 29
300 based on standard curve (Supplementary Fig. 1). Correlation coefficient (R^2) values were 0.99
301 for DENV2 and 0.98 for ZIKV. Based on the standard curve analyses, the limit of detection
302 range was 10 viral RNA copy numbers for DENV2 and ZIKV. Amplification above these values
303 was attributed to non-specific amplification.

304

305 **bCUBE-based qRT-PCR is specific for DENV2 and ZIKV detection**

306 The specificity of the ZIKV and DENV2 assays was then determined using a cross-reactivity
307 panel. To address challenges involving primer cross-reactivity with other arboviruses (46, 48) as
308 well as the tendency toward false-positive amplification in negative samples, we tested the
309 specificity of the assay against a panel of *Flaviviruses* and one *Alphavirus*. The frequently co-
310 circulating arboviral RNA samples, obtained from BEI resources (Table 2) for this study, were:
311 CHIKV (H20235 ST MARTIN 2013), JEV (India R53567), WNV (CO 1862), and YFV (17D).

312 The ZIKV and DENV2 primer pairs showed a high degree of specificity for amplification of
313 their respective virus RNAs (Table 2), since no amplification of other virus RNAs occurred.

Family	Genus	Species	Strain	BEI No.	Result for ZIKV qPCR Assay	Result for DENV-2 qPCR Assay
<i>Flaviviridae</i>	<i>Flavivirus</i>	Zika virus			+	-
		Dengue virus serotype 2			-	+
		Japanese Encephalitis virus	India	NR-9592	-	-
		West Nile virus	CO 1862	NR-50434	-	-
		Yellow Fever virus	17D	NR-2869	-	-
<i>Togaviridae</i>	<i>Alphavirus</i>	Chikungunya virus	St Martin 2013	NR-50130	-	-

314


315 **Table 2. Evaluation of the specificity of bCUBE-based qRT-PCR for DENV2 and ZIKV**
316 **detection**

317 A cross-reactivity panel of frequently co-circulating viruses was used to evaluate the specificity
318 of bCUBE-based qRT-PCR for DENV2 and ZIKV. Arboviral RNA samples were obtained from
319 BEI Resources. The presence of all cross-reactivity panel RNA samples was quantified on
320 NanoDrop for molecular weight and amplified on qRT-PCR with their own primer sequences.
321

322

323 **bCUBE-based qRT-PCR is as accurate as plaque assay in detecting infectious viral RNA**

324 PCR detection of non-infectious viral RNA is possible when viral RNA is not actively
325 replicating (49). Therefore, the viral RNA copy number and viral infectious RNA load can differ
326 in mosquitoes. We thus sought to evaluate the infection prevalence using bCUBE qRT-PCR and
327 plaque assays as opposed to titer comparisons. Three biological replicates of *Ae. aegypti* were
328 infected with ZIKV and DENV-2. Each replicate of infected mosquitoes was collected and
329 separated into two halves to compare infectious prevalence as determined by plaque assay and
330 bCUBE qPCR analysis. In each of the three replicates, no-significant differences were seen in
331 infection prevalence values for both ZIKV and DENV2 between the two methods. These results
332 suggest that bCUBE qRT-PCR analysis can accurately detect infectious ZIKV AND DENV2
333 (Fig. 2).



334


335 **Fig 2. ZIKV AND DENV2 infection prevalence in *Ae. aegypti* as detected in the bCUBE**
336 **versus plaque assay.** *Ae. aegypti* were infected with Zika (A) and dengue (B) virus via an
337 artificial blood meal. Each biological replicate was split into two groups and analyzed using the
338 bCUBE assay (black bars), and the other half was used for the plaque assay (grey bars). No
339 significant difference was detected between the plaque assay and bCUBE qPCR in terms of
340 infectious prevalence (ns: not significant; Fisher's exact test).

341

342 **ZIKV and DENV-2 RNA can be detected and quantified in individual mosquito samples by** 343 **bCUBE assay**

344 *Ae. aegypti* mosquitoes were experimentally infected with ZIKV (n=112) and DENV2 (n=112)
345 through an artificial blood feeder containing anonymous human blood supplemented with virus,
346 and samples from the mosquitoes were evaluated for infection status with the bCUBE platform at
347 7 and 14 days post-blood meal. Samples with Ct values < 30 were considered positive for ZIKV
348 and < 29 for DENV2 infection. Each sample was run in duplicate to confirm infection. Both
349 ZIKV and DENV2 viral RNA were detected from an individually infected mosquito using the
350 squash buffer extraction method and the bCUBE platform. Viral RNA could be detected and

351 quantitated in samples containing single abdomen with midguts and head with thoraces of
352 infected mosquitoes (Fig. 3).




353

354 **Fig 3. Viral RNA concentrations of individual *Ae. aegypti* tissues collected at various time**
355 **points.**

356 Individual *Ae. aegypti* that were infected with Zika (A) and dengue virus (B) were collected at 7
357 or 14 days post-infectious blood meal. Abdomens with midgut samples (ABD) were collected on
358 day 7 post-infectious blood meal, and head with thorax samples (HT) were collected on day 14.
359 Corresponding leg (L) samples were also collected on day 14. Viral RNA extraction was
360 performed using the squash method, followed by amplification using 1-step qPCR on the
361 bCUBE. Uninfected mosquitoes were not included.
362

363 Next we investigated detection of virus in leg samples of *Ae. aegypti* (Fig. 3). Forty-six leg
364 samples were collected from mosquitoes that were also analyzed for infection in the heads and
365 thoraces to confirm infectious status. We found significant differences between the Ct values for
366 the head with thorax samples versus the leg samples. For the leg samples, six false negative
367 sample results were obtained for DENV2, and two false negative results were obtained for
368 ZIKV. One false positive result was detected for ZIKV (Fig. 4). These results indicate that
369 analysis of infection using leg samples is not reliable. No amplification occurred in uninfected

370 *Aedes aegypti* used as a negative control. Because of the false negative results, the DENV2
 371 sensitivity of leg samples was 76% (95% CI, 54.87% to 90.64%) and the diagnostic specificity of
 372 leg samples was 100% (95% CI, 83.89% to 100.00%). The sensitivity for ZIKV of leg samples
 373 was 94.59% (95% CI, 81.81% to 99.34%), and the specificity was 88.89% (95% CI, 51.75% to
 374 99.72%). The overall accuracy of the bCUBE qPCR platform for detecting leg samples was
 375 93.48% for ZIKV (95% CI, 82.10 to 98.63%) and 86.96% for DENV2 (95% CI, 73.75% to
 376 95.06%) (Fig. 4).



377

378 **Fig. 4. Fig. 4. Viral concentration of individual head with thoraces compared to legs.**
 379 Infected *Ae. aegypti* (n=46) were collected, and identical samples of head with thorax and legs
 380 were amplified for Zika virus (A) and DENV2 (B) using bCUBE-based qRT-PCR. Infection
 381 status was compared (****, p<0.0001; paired two-tailed t-test).
 382

383

384 **bCUBE-based qRT-PCR detects ZIKV and DENV-2 viral RNA in pooled *Ae. aegypti***
385 **samples**

386 Surveillance programs monitoring ZIKV and DENV2 transmission will typically assay the
387 presence of virus in pooled samples ranging from 5 to 50 mosquitoes (50). We pooled individual
388 ZIKV- or DENV2-infected mosquitoes with 5, 10, 15, or 20 uninfected *Aedes* in order to assess
389 the assay's sensitivity with pooled samples. The infection status of individual infected
390 mosquitoes was confirmed by viral RNA extraction using squash buffer followed by bCUBE-
391 based qRT-PCR. Following confirmation of infection, positive mosquitoes were placed into four
392 different pools for further viral detection. ZIKV could be detected in all pooled samples. DENV2
393 could be detected in pools of 5, 10, and 15 mosquitoes, but DENV2 viral RNA could not be
394 detected in one of the three biological replicates of the 20-pooled mosquitoes. We found
395 significant differences between the individual infected samples and pooled samples; however,
396 the detection in pooled samples was still within the range for a positive identification
397 (Supplementary Table 1).

398

399 **bCUBE-based qRT-PCR detects *Wolbachia* in individual *Ae. aegypti***

400 *Wolbachia wAlbB* was amplified from individual mosquitoes with qRT-PCR using the bCUBE
401 platform (n=35) (Supplementary Table 2). Uninfected *Ae. aegypti* (n=10) were used as negative
402 controls. All *Wolbachia* -infected mosquitoes were positive for *Wolbachia* infection, and the
403 negative controls did not amplify. These data suggest that bCUBE qPCR can be used for
404 *Wolbachia* detection employing previously established primers.

405

406 **Discussion**

407 Arboviral pathogens represent an expanding threat across the world. Monitoring the vector and
408 its infectious cargo is essential for planning adequate mosquito control to reduce transmission.
409 Endemic countries frequently lack surveillance resources for monitoring pathogen and vector
410 distribution. Therefore, cost-effective field-deployable pathogen detection methods can greatly
411 facilitate surveillance and control efforts. We sought to develop a method for detecting viral
412 pathogens in their *Aedes aegypti* vector with the potential for field deployment. Currently,
413 pathogen detection in the field is limited by expensive lab-based equipment and reactions and the
414 necessity for highly trained personnel to process samples. Real-time qPCR has long been
415 considered the gold standard for viral detection; however, inadequate access to sample
416 preparation methods and the requirement for bulky equipment render this method incompatible
417 with fieldwork.

418
419 As an alternative to laboratory PCR, we have now explored the use of bCUBE, a novel qPCR
420 platform, with a simple nucleic acid extraction method for detection of arboviruses and
421 *Wolbachia* in mosquito vectors. Actions were taken to limit the cost needed for analysis. We
422 used DNA dye binding qPCR commercial kits as an alternative to hydrolysis probe-based qPCR
423 kits. Furthermore, we extracted DNA/RNA using the squash buffer methodology as opposed to
424 expensive extraction kits. It is important to note that current bCUBE cartridges are restricted to
425 16-wells thereby limiting the number of samples run during each experiment. Hyris bCUBE
426 software can be programmed to display results as positive or negative result as opposed to
427 interpreting cycle threshold and melting curve values. This minimizes training for remote
428 personnel.

429

430 We confirmed the reliability of the bCUBE by comparing its performance against laboratory
431 standards. Therefore, bCUBE is capable of performing real-time qPCR while overcoming the
432 barriers presented by the need for bulky equipment. We then employed a crude extraction
433 method using squash buffer to extract viral DENV2 and ZIKV RNA from mosquitoes for use in
434 the bCUBE system. To address challenges involving primer cross-reactivity with other
435 arboviruses (46, 48) as well as the tendency toward false-positive amplification in negative
436 samples, we tested the specificity of the assay against a panel of frequently co-circulating
437 arboviruses. The results confirmed the assay's specificity for DENV2 and ZIKV RNA, with the
438 potential to apply these primer pairs for field conditions. To negate any non-specific
439 amplification of the host's genetic material, we used a standard curve to determine the limit of
440 detection and subsequently, the cut off values for detecting ZIKV and DENV2. This allowed for
441 positive identification of viral RNA from infected mosquito samples while limiting the
442 amplification of false positive samples as a result of background noise. Following primer
443 optimization, we compared the bCUBE assay to plaque assays for determining infection
444 prevalence. Because qPCR is generally capable of detecting low RNA copy numbers in
445 individual samples, it is important to evaluate the assay's potential for detecting infectious viral
446 RNA rather than viral RNA that is not replicating (49, 51). No significant differences were seen
447 between the bCUBE and plaque assay for three biological replicates, suggesting that the bCUBE
448 assay is able to detect infectious viral RNA.

449

450 We evaluated the use of *Ae. aegypti* leg samples for viral detection. Some infected leg samples
451 turned out to be false negatives suggesting this sample type is unreliable for assaying virus.
452 However, mosquito surveillance agencies typically evaluate arboviral infection status in pooled

453 samples as opposed to assaying individual mosquitoes. ZIKV RNA was detected in pools of 5,
454 10, 15, and 20 with uninfected mosquitoes in three biological replicates. DENV RNA was not
455 detected in one of three biological replicates of 20-mosquito pools, suggesting possible
456 limitations for DENV detection. This highlights the bCUBE platform's potential for pool testing
457 in the field.

458

459 Given RNA's inherent instability and frequency of mutation, it is likely for sequence variability
460 to occur under field conditions. Therefore, it is important to vigilantly monitor the viral strains
461 that are co-circulating in a region to accurately and specifically detect viral RNA in mosquitoes
462 when applying this methodology in the field. It is critical to perform absolute quantification
463 analyses and determine end-point limitation values during optimization to avoid amplification of
464 false positive samples as a result of qPCR background noise. Potential future studies involve
465 bringing the portable platform into the field to analyze its feasibility for performing qPCR under
466 true field conditions. The versatility of the assay can be applied to future studies involving
467 *Plasmodium falciparum* detection in *Anopheles* species and monitoring of various species of the
468 *Anopheles* vector as well as detecting insecticide resistance in field-caught mosquitoes.

469

470 **Conclusion**

471 We have developed a highly sensitive qPCR method for detection and quantitation of DENV2
472 and ZIKV in single mosquitoes using the portable qPCR Hyris bCUBE platform. Our assay
473 allowed for sensitive and reliable DENV2 and ZIKV detection that make it a potential tool for
474 mosquito surveillance programs in endemic countries facing arboviral outbreaks. The detection
475 of *Wolbachia* in *Ae. aegypti* further demonstrates the platform's ability to be used as a multi-

476 detection assay. By overcoming the challenges of costs associated with reagents and equipment,
477 the bCUBE qPCR platform provides a potential field-deployable laboratory resources for
478 mosquito surveillance agencies in remote regions.

479

480 **Acknowledgments**

481 The authors thank Hyris, Inc. for providing the bCUBE and Mr Stefano Lo Priore and Mr
482 Lorenzo Colombo for technical advices. We also thank Dr. Zhiyong Xi from Michigan State
483 University for kindly providing *Wolbachia wAlbB*-infected *Ae. aegypti* strain WB1 and Dr.
484 Deborah McClellan for editorial assistance. We thank the Johns Hopkins Malaria Research
485 Institute Insectary core facility. This work has been supported by the National Institutes of
486 Health grant R21AI136456, and the Bloomberg Philanthropies.

487

488 **References**

- 489 1. Lee H, Halverson S, Ezinwa N. Mosquito-Borne Diseases. *Prim Care*. 2018;45(3):393-407.
- 490 2. Yun SI, Lee YM. Zika virus: An emerging flavivirus. *J Microbiol*. 2017;55(3):204-19.
- 491 3. Epelboin Y, Talaga S, Epelboin L, Dusfour I. Zika virus: An updated review of competent or
492 naturally infected mosquitoes. *PLoS Negl Trop Dis*. 2017;11(11):e0005933.
- 493 4. Esser HJ, Mögling R, Cleton NB, van der Jeugd H, Sprong H, Stroo A, et al. Risk factors
494 associated with sustained circulation of six zoonotic arboviruses: a systematic review for
495 selection of surveillance sites in non-endemic areas. *Parasit Vectors*. 2019;12(1):265.
- 496 5. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global
497 distribution and burden of dengue. *Nature*. 2013;496(7446):504-7.
- 498 6. Guo C, Zhou Z, Wen Z, Liu Y, Zeng C, Xiao D, et al. Global Epidemiology of Dengue
499 Outbreaks in 1990-2015: A Systematic Review and Meta-Analysis. *Front Cell Infect*
500 *Microbiol*. 2017;7:317.
- 501 7. Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika Virus. *N Engl J Med*.
502 2016;374(16):1552-63.
- 503 8. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika Virus and Birth Defects--
504 Reviewing the Evidence for Causality. *N Engl J Med*. 2016;374(20):1981-7.
- 505 9. Ayres CF. Identification of Zika virus vectors and implications for control. *Lancet Infect Dis*.
506 2016;16(3):278-9.
- 507 10. Patterson J, Sammon M, Garg M. Dengue, Zika and Chikungunya: Emerging Arboviruses in
508 the New World. *West J Emerg Med*. 2016;17(6):671-9.

- 509 11. Weaver SC, Reisen WK. Present and future arboviral threats. *Antiviral Res.* 2010;85(2):328-
510 45.
- 511 12. Benelli G, Mehlhorn H. Declining malaria, rising of dengue and Zika virus: insights for
512 mosquito vector control. *Parasitol Res.* 2016;115(5):1747-54.
- 513 13. Kraemer MUG, Reiner RC, Jr., Brady OJ, Messina JP, Gilbert M, Pigott DM, et al. Past and
514 future spread of the arbovirus vectors *Aedes aegypti* and *Aedes albopictus*. *Nat Microbiol.*
515 2019;4(5):854-63.
- 516 14. Lequime S, Richard V, Cao-Lormeau VM, Lambrechts L. Full-genome dengue virus
517 sequencing in mosquito saliva shows lack of convergent positive selection during
518 transmission by *Aedes aegypti*. *Virus Evol.* 2017;3(2):vex031.
- 519 15. Ayllon T, Campos RM, Brasil P, Morone FC, Camara DCP, Meira GLS, et al. Early
520 Evidence for Zika Virus Circulation among *Aedes aegypti* Mosquitoes, Rio de Janeiro,
521 Brazil. *Emerg Infect Dis.* 2017;23(8):1411-2.
- 522 16. Walker T, Johnson PH, Moreira LA, Iturbe-Ormaetxe I, Frentiu FD, McMeniman CJ, et al.
523 The wMel *Wolbachia* strain blocks dengue and invades caged *Aedes aegypti* populations.
524 *Nature.* 2011;476(7361):450-3.
- 525 17. Dutra HL, Rocha MN, Dias FB, Mansur SB, Caragata EP, Moreira LA. *Wolbachia* Blocks
526 Currently Circulating Zika Virus Isolates in Brazilian *Aedes aegypti* Mosquitoes. *Cell Host*
527 *Microbe.* 2016;19(6):771-4.
- 528 18. Kamtchum-Tatuene J, Makepeace BL, Benjamin L, Baylis M, Solomon T. The potential role
529 of *Wolbachia* in controlling the transmission of emerging human arboviral infections. *Curr*
530 *Opin Infect Dis.* 2017;30(1):108-16.
- 531 19. Garcia GA, Sylvestre G, Aguiar R, da Costa GB, Martins AJ, Lima JBP, et al. Matching the
532 genetics of released and local *Aedes aegypti* populations is critical to assure *Wolbachia*
533 invasion. *PLoS Negl Trop Dis.* 2019;13(1):e0007023.
- 534 20. Flores HA, O'Neill SL. Controlling vector-borne diseases by releasing modified mosquitoes.
535 *Nat Rev Microbiol.* 2018;16(8):508-18.
- 536 21. Joubert DA, O'Neill SL. Comparison of Stable and Transient *Wolbachia* Infection Models in
537 *Aedes aegypti* to Block Dengue and West Nile Viruses. *PLoS Negl Trop Dis.*
538 2017;11(1):e0005275.
- 539 22. Waggoner JJ, Pinsky BA. Zika Virus: Diagnostics for an Emerging Pandemic Threat. *J Clin*
540 *Microbiol.* 2016;54(4):860-7.
- 541 23. Nasci RS, Gottfried KL, Burkhalter KL, Kulasekera VL, Lambert AJ, Lanciotti RS, et al.
542 Comparison of vero cell plaque assay, TaqMan reverse transcriptase polymerase chain
543 reaction RNA assay, and VecTest antigen assay for detection of West Nile virus in field-
544 collected mosquitoes. *J Am Mosq Control Assoc.* 2002;18(4):294-300.
- 545 24. Ramírez AL, van den Hurk AF, Meyer DB, Ritchie SA. Searching for the proverbial needle
546 in a haystack: advances in mosquito-borne arbovirus surveillance. *Parasit Vectors.*
547 2018;11(1):320.
- 548 25. Burkhalter KL, Wiggins K, Burkett-Cadena N, Alto BW. Laboratory Evaluation of
549 Commercially Available Platforms to Detect West Nile and Zika Viruses From Honey Cards.
550 *J Med Entomol.* 2018;55(3):717-22.
- 551 26. Girod R, Guidez A, Carinci R, Issaly J, Gaborit P, Ferrero E, et al. Detection of Chikungunya
552 Virus Circulation Using Sugar-Baited Traps during a Major Outbreak in French Guiana.
553 *PLoS Negl Trop Dis.* 2016;10(9):e0004876.

- 554 27. Yaren O, Alto BW, Gangodkar PV, Ranade SR, Patil KN, Bradley KM, et al. Point of
555 sampling detection of Zika virus within a multiplexed kit capable of detecting dengue and
556 chikungunya. *BMC Infect Dis*. 2017;17(1):293.
- 557 28. Wasik D, Mulchandani A, Yates MV. Point-of-Use Nanobiosensor for Detection of Dengue
558 Virus NS1 Antigen in Adult *Aedes aegypti*: A Potential Tool for Improved Dengue
559 Surveillance. *Analytical Chemistry*. 2018;90(1):679-84.
- 560 29. Fernandes JN, dos Santos LMB, Chouin-Carneiro T, Pavan MG, Garcia GA, David MR, et
561 al. Rapid, noninvasive detection of Zika virus in *Aedes aegypti* mosquitoes by
562 near-infrared spectroscopy. *Science Advances*. 2018;4(5):eaat0496.
- 563 30. Singh RK, Dhama K, Karthik K, Tiwari R, Khandia R, Munjal A, et al. Advances in
564 Diagnosis, Surveillance, and Monitoring of Zika Virus: An Update. *Front Microbiol*.
565 2017;8:2677.
- 566 31. Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, et
567 al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection
568 with zika virus. *Nat Immunol*. 2016;17(9):1102-8.
- 569 32. Benelli G. Managing mosquitoes and ticks in a rapidly changing world - Facts and trends.
570 *Saudi J Biol Sci*. 2019;26(5):921-9.
- 571 33. Molyneux DH, Savioli L, Engels D. Neglected tropical diseases: progress towards addressing
572 the chronic pandemic. *Lancet*. 2017;389(10066):312-25.
- 573 34. Tien WP, Lim G, Yeo G, Chiang SN, Chong CS, Ng LC, et al. SYBR green-based one step
574 quantitative real-time polymerase chain reaction assay for the detection of Zika virus in field-
575 caught mosquitoes. *Parasit Vectors*. 2017;10(1):427.
- 576 35. Xu MY, Liu SQ, Deng CL, Zhang QY, Zhang B. Detection of Zika virus by SYBR green
577 one-step real-time RT-PCR. *J Virol Methods*. 2016;236:93-7.
- 578 36. Charrel RN, Leparac-Goffart I, Pas S, de Lamballerie X, Koopmans M, Reusken C.
579 Background review for diagnostic test development for Zika virus infection. *Bull World*
580 *Health Organ*. 2016;94(8):574-84d.
- 581 37. Das S, Garver L, Ramirez JR, Xi Z, Dimopoulos G. Protocol for dengue infections in
582 mosquitoes (*A. aegypti*) and infection phenotype determination. *J Vis Exp*. 2007(5):220.
- 583 38. Xi Z, Khoo CC, Dobson SL. Wolbachia establishment and invasion in an *Aedes aegypti*
584 laboratory population. *Science*. 2005;310(5746):326-8.
- 585 39. Sim S, Ramirez JL, Dimopoulos G. Dengue virus infection of the *Aedes aegypti* salivary
586 gland and chemosensory apparatus induces genes that modulate infection and blood-feeding
587 behavior. *PLoS Pathog*. 2012;8(3):e1002631.
- 588 40. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, et al. Genetic and
589 serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007.
590 *Emerg Infect Dis*. 2008;14(8):1232-9.
- 591 41. Frentiu FD, Zakir T, Walker T, Popovici J, Pyke AT, van den Hurk A, et al. Limited dengue
592 virus replication in field-collected *Aedes aegypti* mosquitoes infected with Wolbachia. *PLoS*
593 *Negl Trop Dis*. 2014;8(2):e2688.
- 594 42. Axford JK, Ross PA, Yeap HL, Callahan AG, Hoffmann AA. Fitness of wAlbB Wolbachia
595 Infection in *Aedes aegypti*: Parameter Estimates in an Outcrossed Background and Potential
596 for Population Invasion. *Am J Trop Med Hyg*. 2016;94(3):507-16.
- 597 43. Danet L, Beauclair G, Berthet M, Moratorio G, Gracias S, Tangy F, et al. Midgut barriers
598 prevent the replication and dissemination of the yellow fever vaccine in *Aedes aegypti*. *PLoS*
599 *Negl Trop Dis*. 2019;13(8):e0007299.

- 600 44. Lanciotti RS, Kerst AJ, Nasci RS, Godsey MS, Mitchell CJ, Savage HM, et al. Rapid
601 detection of west nile virus from human clinical specimens, field-collected mosquitoes, and
602 avian samples by a TaqMan reverse transcriptase-PCR assay. *J Clin Microbiol.*
603 2000;38(11):4066-71.
- 604 45. Khan SA, Borah J, Chowdhury P, Dutta P, Mahanta J. Characterization of Japanese
605 encephalitis virus (JEV) genotype III clinical isolates in northeast India. *Trans R Soc Trop*
606 *Med Hyg.* 2015;109(8):522-8.
- 607 46. Wu W, Wang J, Yu N, Yan J, Zhuo Z, Chen M, et al. Development of multiplex real-time
608 reverse-transcriptase polymerase chain reaction assay for simultaneous detection of Zika,
609 dengue, yellow fever, and chikungunya viruses in a single tube. *J Med Virol.*
610 2018;90(11):1681-6.
- 611 47. Goncalves DDS, Hooker DJ, Dong Y, Baran N, Kyrylos P, Iturbe-Ormaetxe I, et al.
612 Detecting wMel Wolbachia in field-collected *Aedes aegypti* mosquitoes using loop-mediated
613 isothermal amplification (LAMP). *Parasit Vectors.* 2019;12(1):404.
- 614 48. Carrillo-Hernandez MY, Ruiz-Saenz J, Villamizar LJ, Gomez-Rangel SY, Martinez-
615 Gutierrez M. Co-circulation and simultaneous co-infection of dengue, chikungunya, and zika
616 viruses in patients with febrile syndrome at the Colombian-Venezuelan border. *BMC Infect*
617 *Dis.* 2018;18(1):61.
- 618 49. Aubry M, Richard V, Green J, Broult J, Musso D. Inactivation of Zika virus in plasma with
619 amotosalen and ultraviolet A illumination. *Transfusion.* 2016;56(1):33-40.
- 620 50. Gu W, Lampman R, Novak RJ. Assessment of arbovirus vector infection rates using variable
621 size pooling. *Med Vet Entomol.* 2004;18(2):200-4.
- 622 51. Musso D, Richard V, Broult J, Cao-Lormeau VM. Inactivation of dengue virus in plasma
623 with amotosalen and ultraviolet A illumination. *Transfusion.* 2014;54(11):2924-30.
624